NCT02958592

Brief Summary

To evaluate the diagnostic performance of two-dimensional shear-wave elastography (SWE) for staging hepatic fibrosis in the background liver parenchyma in patients with liver tumors before hepatic resection, using resected tissue pathology as a reference standard.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
121

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2015

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2015

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2016

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2016

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

November 5, 2016

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 8, 2016

Completed
Last Updated

November 8, 2016

Status Verified

November 1, 2016

Enrollment Period

9 months

First QC Date

November 5, 2016

Last Update Submit

November 5, 2016

Conditions

Keywords

shear-wave elastographyhepatic fibrosisliver tumor

Outcome Measures

Primary Outcomes (1)

  • Stage of hepatic fibrosis

    compare the stage of hepatic fibrosis between SWE test with specimens after surgery

    within the first 7 days after surgery

Study Arms (1)

study group

patients with liver tumor intend to perform hepatectomy

Other: two-dimensional shear-wave elastography (SWE)

Interventions

performa two-dimensional shear-wave elastography (SWE) for staging hepatic fibrosis in the background liver parenchyma in patients with liver tumors before hepatic resection

study group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed with liver tumor intend to hepatectomy

You may qualify if:

  • (i) patients with a solid focal liver lesion that was pathologically proven or diagnosed by imaging methods such as conventional US, CT or MR imaging; (ii) patients scheduled to undergo a hepatectomy; (iii) patients with a lesion ≥1.0 cm in diameter.

You may not qualify if:

  • (i) patients with a history of chemotherapy; (ii) patients unable to properly hold their breath.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Huang Z, Zheng W, Zhang YJ, Xu L, Chen JB, Chen JC, Chen MS, Zhou Z. Assessing Hepatic Fibrosis Using 2-D Shear Wave Elastography in Patients with Liver Tumors: A Prospective Single-Center Study. Ultrasound Med Biol. 2017 Nov;43(11):2522-2529. doi: 10.1016/j.ultrasmedbio.2017.07.003. Epub 2017 Aug 12.

MeSH Terms

Conditions

Carcinoma, HepatocellularLiver Cirrhosis

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver DiseasesFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Minshan Chen

    Sun Yat-sen University

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

November 5, 2016

First Posted

November 8, 2016

Study Start

June 1, 2015

Primary Completion

March 1, 2016

Study Completion

October 1, 2016

Last Updated

November 8, 2016

Record last verified: 2016-11

Data Sharing

IPD Sharing
Will not share